CN104334524B - 含氟氨基酸的前药 - Google Patents

含氟氨基酸的前药 Download PDF

Info

Publication number
CN104334524B
CN104334524B CN201380028764.5A CN201380028764A CN104334524B CN 104334524 B CN104334524 B CN 104334524B CN 201380028764 A CN201380028764 A CN 201380028764A CN 104334524 B CN104334524 B CN 104334524B
Authority
CN
China
Prior art keywords
carbonyl
hexane
amino
oxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380028764.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104334524A (zh
Inventor
端早田隆
大岳宪
大岳宪一
宫腰直树
坂上成
坂上一成
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of CN104334524A publication Critical patent/CN104334524A/zh
Application granted granted Critical
Publication of CN104334524B publication Critical patent/CN104334524B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C07D317/40—Vinylene carbonate; Substituted vinylene carbonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380028764.5A 2012-06-01 2013-05-31 含氟氨基酸的前药 Active CN104334524B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2012-126162 2012-06-01
JP2012126162 2012-06-01
JP2013052574 2013-03-15
JP2013-052574 2013-03-15
PCT/JP2013/065202 WO2013180271A1 (ja) 2012-06-01 2013-05-31 含フッ素アミノ酸のプロドラッグ

Publications (2)

Publication Number Publication Date
CN104334524A CN104334524A (zh) 2015-02-04
CN104334524B true CN104334524B (zh) 2016-10-12

Family

ID=49673454

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380028764.5A Active CN104334524B (zh) 2012-06-01 2013-05-31 含氟氨基酸的前药

Country Status (32)

Country Link
US (1) US9428483B2 (enExample)
EP (1) EP2857385B1 (enExample)
JP (1) JP5979230B2 (enExample)
KR (1) KR102062936B1 (enExample)
CN (1) CN104334524B (enExample)
AU (1) AU2013268303B2 (enExample)
BR (1) BR112014029478B1 (enExample)
CA (1) CA2875080C (enExample)
CY (1) CY1119646T1 (enExample)
DK (1) DK2857385T3 (enExample)
ES (1) ES2637986T3 (enExample)
HR (1) HRP20171373T1 (enExample)
HU (1) HUE034513T2 (enExample)
IL (1) IL235897B (enExample)
IN (1) IN2014DN10538A (enExample)
LT (1) LT2857385T (enExample)
ME (1) ME02833B (enExample)
MX (1) MX355161B (enExample)
MY (1) MY169069A (enExample)
NO (1) NO2857385T3 (enExample)
NZ (1) NZ702237A (enExample)
PH (1) PH12014502670B1 (enExample)
PL (1) PL2857385T3 (enExample)
PT (1) PT2857385T (enExample)
RS (1) RS56328B1 (enExample)
RU (1) RU2639868C1 (enExample)
SG (1) SG11201407973SA (enExample)
SI (1) SI2857385T1 (enExample)
SM (1) SMT201700486T1 (enExample)
TW (1) TWI602801B (enExample)
WO (1) WO2013180271A1 (enExample)
ZA (1) ZA201408857B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2909160C (en) 2013-04-09 2021-05-25 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
JP5983713B2 (ja) * 2013-11-29 2016-09-06 大正製薬株式会社 含フッ素アミノ酸のプロドラッグを含有する医薬
JP5983714B2 (ja) * 2013-11-29 2016-09-06 大正製薬株式会社 含フッ素アミノ酸プロドラッグの結晶形とその製造方法
MX2016008110A (es) * 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
EP3736275B1 (en) * 2015-05-15 2024-07-03 Lixte Biotechnology, Inc. Oxabicycloheptane prodrugs for use in treating cancer
AU2017254266B2 (en) 2016-04-18 2021-03-11 Taisho Pharmaceutical Co., Ltd. Prodrug of amino acid derivative
JP7246309B2 (ja) 2016-12-08 2023-03-27 リクスト・バイオテクノロジー，インコーポレイテッド 免疫応答を調節するためのオキサビシクロヘプタン
JP7314494B2 (ja) * 2017-10-17 2023-07-26 大正製薬株式会社 アミノ酸誘導体のプロドラッグを含有する医薬
CN119059935A (zh) * 2024-11-07 2024-12-03 安徽金禾合成材料研究院有限公司 一种采用前馏分溶剂法合成2,2-二异丙基丙腈的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1295557A (zh) * 1998-01-28 2001-05-16 大正制药株式会社 含氟氨基酸衍生物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4171549B2 (ja) * 1998-01-28 2008-10-22 大正製薬株式会社 含フッ素アミノ酸誘導体
ES2226472T3 (es) 1998-12-18 2005-03-16 Taisho Pharmaceutical Co., Ltd Intermedios y procedimiento para producir un compuesto de aminoacido que contiene fluor utilizando dichos intermedios.
JP4783967B2 (ja) * 1999-07-21 2011-09-28 大正製薬株式会社 含フッ素アミノ酸誘導体を有効成分とする医薬
RU2315622C2 (ru) * 2001-12-27 2008-01-27 Тайсо Фармасьютикал Ко.,Лтд. Производные 6-фторбицикло[3.1.0]гексана
CN101362793A (zh) 2002-06-11 2009-02-11 伊莱利利公司 兴奋性氨基酸前药
HRP20090058A2 (hr) 2002-06-11 2009-04-30 Eli Lilly And Company Prekursorski oblici lijekova za aminokiseline s pobuđivačkom aktivnosti
JP5983713B2 (ja) * 2013-11-29 2016-09-06 大正製薬株式会社 含フッ素アミノ酸のプロドラッグを含有する医薬
JP5983714B2 (ja) * 2013-11-29 2016-09-06 大正製薬株式会社 含フッ素アミノ酸プロドラッグの結晶形とその製造方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1295557A (zh) * 1998-01-28 2001-05-16 大正制药株式会社 含氟氨基酸衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Stereoselective Synthesis of 2-Amino-3-fluoro Bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid;Concepcion Pedregal et al.;《Bioorganic & Medicinal Chemistry》;20021231;第10卷;433–436 *

Also Published As

Publication number Publication date
ME02833B (me) 2018-01-20
KR20150016248A (ko) 2015-02-11
JPWO2013180271A1 (ja) 2016-01-21
US20150141669A1 (en) 2015-05-21
ES2637986T3 (es) 2017-10-18
EP2857385A1 (en) 2015-04-08
TWI602801B (zh) 2017-10-21
BR112014029478B1 (pt) 2023-01-17
SI2857385T1 (sl) 2017-10-30
PL2857385T3 (pl) 2018-01-31
WO2013180271A1 (ja) 2013-12-05
NO2857385T3 (enExample) 2017-12-30
US9428483B2 (en) 2016-08-30
PT2857385T (pt) 2017-11-08
SG11201407973SA (en) 2015-01-29
PH12014502670A1 (en) 2015-02-02
MY169069A (en) 2019-02-12
PH12014502670B1 (en) 2015-02-02
CA2875080C (en) 2020-03-24
RU2639868C1 (ru) 2017-12-25
HUE034513T2 (en) 2018-02-28
CN104334524A (zh) 2015-02-04
DK2857385T3 (en) 2017-09-11
EP2857385A4 (en) 2015-11-11
KR102062936B1 (ko) 2020-01-06
TW201408627A (zh) 2014-03-01
IL235897B (en) 2019-09-26
BR112014029478A8 (pt) 2021-03-16
IL235897A0 (en) 2015-02-01
MX2014014642A (es) 2015-02-12
SMT201700486T1 (it) 2017-11-15
JP5979230B2 (ja) 2016-08-24
IN2014DN10538A (enExample) 2015-08-21
CY1119646T1 (el) 2018-04-04
ZA201408857B (en) 2016-08-31
EP2857385B1 (en) 2017-08-02
CA2875080A1 (en) 2013-12-05
HRP20171373T1 (hr) 2017-11-03
MX355161B (es) 2018-04-06
NZ702237A (en) 2016-08-26
HK1202526A1 (en) 2015-10-02
AU2013268303B2 (en) 2017-01-05
LT2857385T (lt) 2017-10-25
AU2013268303A1 (en) 2014-12-18
BR112014029478A2 (pt) 2017-06-27
RS56328B1 (sr) 2017-12-29

Similar Documents

Publication Publication Date Title
CN104334524B (zh) 含氟氨基酸的前药
TWI813666B (zh) 一種多功能化合物、其製備方法及其在醫藥上的應用
JP7072690B2 (ja) ブルトン型チロシンキナーゼの阻害剤としての多環式化合物
WO2019000683A1 (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
EP3126349B1 (en) 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists
CN116348447A (zh) Apol1的抑制剂及其使用其的方法
TWI739779B (zh) 布魯頓氏酪胺酸激酶抑制劑及其使用方法
WO2005065195A2 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
CN115772159A (zh) Kif18a抑制剂
CN117295740A (zh) 含有亚磺酰亚胺基的atr抑制剂化合物
WO2023041055A1 (zh) Kif18a抑制剂
CN105143176A (zh) 白纹黄单胞菌毒素衍生物、其用途以及合成
JP5635181B2 (ja) ニトロイミダゾール系化合物、その製造方法および用途
WO2022199599A1 (zh) 丙烯酰基取代的化合物、包含其的药物组合物及其用途
JP5983713B2 (ja) 含フッ素アミノ酸のプロドラッグを含有する医薬
JP2008519046A (ja) キノリン化合物およびそれから得られる生成物の調製方法
HK1202526B (en) Prodrug of fluorine-containing amino acid
CN114746089A (zh) 噻唑甲酰胺化合物及其用于治疗分枝杆菌感染的用途
TW202543607A (zh) 介白素１７ａ抑制劑及其用途
WO2025196623A1 (en) Indole analogs
HK40066473A (zh) 用作选择性aurora a抑制剂的新型杂环化合物
HK40052204B (en) Polycyclic compounds as inhibitors of bruton's tyrosine kinase
HK40052204A (en) Polycyclic compounds as inhibitors of bruton's tyrosine kinase
HK40048952B (zh) 杂环类化合物、中间体、其制备方法及应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1202526

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1202526

Country of ref document: HK